Frank H. Wians
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Frank H. Wians has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Torabi
Paul L. Foster School of Medicine, Department of Pathology, United States
1 shared publication Andrea Horsch
Roche Diagnostics International, Switzerland
1 shared publicationAnn-Kathrin Wiedergruen
University of Heidelberg, Heidelberg, Germany
1 shared publicationAnna Corletto
University of Heidelberg, Heidelberg, Germany
1 shared publicationBrad A. Bryan
Department of Biomedical Sciences, Texas Tech University Health Sciences Center, El Paso, TX, United States
1 shared publication- Bradford Ray
Patient Blood Management and Research University Medical Center El Paso TX USA
1 shared publication
Latest Publications
- Open Access
- 23 September 2021
- Published by Wiley in Vox Sanguinis
- Vol. 117 (3) , 299-312
Transfusion management of trauma from the 2019 El Paso mass shooting incident
Background and Objectives Mortality rates, transfusion ratios, trauma management logistics, and assault characteristics from the El Paso mass shooting incident (MSI) are evaluated in comparison to other MSIs. In 2019, El Paso, TX experienced the eighth-deadliest MSIs in modern US history. In this 21st mass killing in the United States of 2019, 19 people died immediately, and four of 27 injured, later died from ballistic injuries. Materials and Methods We examined the victims' injuries, pre-hospital treatments, transfusions, rotational thromboelastometry (ROTEM) interpretation, tranexamic acid (TXA) use, and compared El Paso's outcomes with other MSIs. Results Fifteen casualties were treated for bullet injuries at University Medical Center (UMC). Three were in critical condition; one died during surgery. Of the remaining victims, two were guarded, and the remaining ten in stable condition. Anatomic trauma locations included chest, abdomen, hip, breast, thigh and arm. Haemostatic agents and TXA were administered to arriving patients. Seven casualties receiving blood products were administered 95 units at UMC (45 red blood cells [RBC], 38 fresh frozen plasma [FFP], 8 platelets and 4 cryoprecipitate). ROTEM guided mass transfusion decisions in three patients. Out of seven MSIs reviewed, El Paso had the highest mortality rate (50.0%) and lowest RBC:FFP:admission ratio (1.18 at UMC). Conclusion We report the greatest proportion of transfusions per admission for an MSI and are first to discuss ROTEM roles to guide transfusion and manage coagulopathy during an MSI. This case highlights the severity and impact of MSIs on victims and requirements to follow established transfusion protocols with adjunct use of ROTEM, TXA and haemostatic agents.
- 23 September 2021
- Published by Wiley in Vox Sanguinis
- Vol. 117 (3) , 299-312
Open AccessTransfusion management of trauma from the 2019 El Paso mass shooting incident
Background and Objectives Mortality rates, transfusion ratios, trauma management logistics, and assault characteristics from the El Paso mass shooting incident (MSI) are evaluated in comparison to other MSIs. In 2019, El Paso, TX experienced the eighth-deadliest MSIs in modern US history. In this 21st mass killing in the United States of 2019, 19 people died immediately, and four of 27 injured, later died from ballistic injuries. Materials and Methods We examined the victims' injuries, pre-hospital treatments, transfusions, rotational thromboelastometry (ROTEM) interpretation, tranexamic acid (TXA) use, and compared El Paso's outcomes with other MSIs. Results Fifteen casualties were treated for bullet injuries at University Medical Center (UMC). Three were in critical condition; one died during surgery. Of the remaining victims, two were guarded, and the remaining ten in stable condition. Anatomic trauma locations included chest, abdomen, hip, breast, thigh and arm. Haemostatic agents and TXA were administered to arriving patients. Seven casualties receiving blood products were administered 95 units at UMC (45 red blood cells [RBC], 38 fresh frozen plasma [FFP], 8 platelets and 4 cryoprecipitate). ROTEM guided mass transfusion decisions in three patients. Out of seven MSIs reviewed, El Paso had the highest mortality rate (50.0%) and lowest RBC:FFP:admission ratio (1.18 at UMC). Conclusion We report the greatest proportion of transfusions per admission for an MSI and are first to discuss ROTEM roles to guide transfusion and manage coagulopathy during an MSI. This case highlights the severity and impact of MSIs on victims and requirements to follow established transfusion protocols with adjunct use of ROTEM, TXA and haemostatic agents.
- 28 July 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (12) , 835-842
Hemodynamic Determinants of the Biologic Variation of N-Terminal Pro–B-Type Natriuretic Peptide in Patients With Stable Systolic Chronic Heart Failure
- 28 July 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (12) , 835-842
Hemodynamic Determinants of the Biologic Variation of N-Terminal Pro–B-Type Natriuretic Peptide in Patients With Stable Systolic Chronic Heart Failure
- 8 December 2006
- Published by Wiley in International Journal of Urology
- Vol. 14 (3) , 251-253
Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: Interference by human antimouse heterophile antibodies
Human antimouse heterophile antibodies (HAMA) are naturally occurring antibodies that can interfere with modern serum assays. We report a case of HAMA interference with a commonly used prostate-specific antigen (PSA) assay, leading to false elevation (2.17-2.46 ng/mL) after radical prostatectomy. Pre-operative PSA was 4.4 ng/mL, and final pathology was Gleason 3 + 3, pT2cNXMX. This markedly elevated postoperative PSA led to unnecessary imaging for metastasis and psychological distress to the patient. Direct measurement of HAMA in the patient's serum yielded a value of 440 ng/mL (<74 ng/mL). An alternate PSA assay using goat detection antibody eliminated interference, with all values 0.05 ng/mL. When a patient's PSA is inconsistent with the clinical scenario, one should consider immunological interference by HAMA in PSA assays.
- 8 December 2006
- Published by Wiley in International Journal of Urology
- Vol. 14 (3) , 251-253
Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: Interference by human antimouse heterophile antibodies
Human antimouse heterophile antibodies (HAMA) are naturally occurring antibodies that can interfere with modern serum assays. We report a case of HAMA interference with a commonly used prostate-specific antigen (PSA) assay, leading to false elevation (2.17-2.46 ng/mL) after radical prostatectomy. Pre-operative PSA was 4.4 ng/mL, and final pathology was Gleason 3 + 3, pT2cNXMX. This markedly elevated postoperative PSA led to unnecessary imaging for metastasis and psychological distress to the patient. Direct measurement of HAMA in the patient's serum yielded a value of 440 ng/mL (<74 ng/mL). An alternate PSA assay using goat detection antibody eliminated interference, with all values 0.05 ng/mL. When a patient's PSA is inconsistent with the clinical scenario, one should consider immunological interference by HAMA in PSA assays.
- Open Access
- 7 December 1998
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 12 (5) , 280-284
Comparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods
Three hospital sites evaluated the Bayer two‐pad urine dipstick as a screening test for microalbuminuria. One pad estimates albumin concentrations between 10 and 150 mg/L, and the second estimates creatinine values between 300 and 3,000 mg/L. The Boehringer Mannheim (BMD) Micral® dipstick was also compared and evaluated. The accuracy of the dipsticks was judged by comparison with cuvet‐based immunonephelometry for albumin and to standard rate‐Jaffé methods for creatinine; these assays were well standardized and controlled and were assumed to give accurate values. Precision of these methods and that of the dipsticks was determined by multiple assays of control materials. Visual or instrument (Clinitek 50® or 100®) evaluation of the Bayer or visual checks of the BMD albumin dipstick pad with patients' urines gave clinically acceptable accuracy. The albumin/creatinine ratio from the Bayer dipsticks gave better accuracy for albumin excretion than the albumin pads alone from either manufacturer. This ratio should permit making a good estimate of the 24‐hr albumin excretion in a randomly collected urine. J. Clin. Lab. Anal. 12:280–284, 1998.
- 7 December 1998
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 12 (5) , 280-284
Open AccessComparison of instrument-read dipsticks for albumin and creatinine in urine with visual results and quantitative methods
Three hospital sites evaluated the Bayer two‐pad urine dipstick as a screening test for microalbuminuria. One pad estimates albumin concentrations between 10 and 150 mg/L, and the second estimates creatinine values between 300 and 3,000 mg/L. The Boehringer Mannheim (BMD) Micral® dipstick was also compared and evaluated. The accuracy of the dipsticks was judged by comparison with cuvet‐based immunonephelometry for albumin and to standard rate‐Jaffé methods for creatinine; these assays were well standardized and controlled and were assumed to give accurate values. Precision of these methods and that of the dipsticks was determined by multiple assays of control materials. Visual or instrument (Clinitek 50® or 100®) evaluation of the Bayer or visual checks of the BMD albumin dipstick pad with patients' urines gave clinically acceptable accuracy. The albumin/creatinine ratio from the Bayer dipsticks gave better accuracy for albumin excretion than the albumin pads alone from either manufacturer. This ratio should permit making a good estimate of the 24‐hr albumin excretion in a randomly collected urine. J. Clin. Lab. Anal. 12:280–284, 1998.